Protalix BioTherapeutics, Inc.
PLX
$2.22
-$0.14-5.93%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 30.14% | 27.80% | -1.23% | 35.42% | 62.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.14% | 27.80% | -1.23% | 35.42% | 62.79% |
| Cost of Revenue | 13.00% | -1.06% | 25.02% | -15.27% | -8.15% |
| Gross Profit | 58.66% | 97.60% | -58.91% | 37,317.74% | 671.40% |
| SG&A Expenses | 16.60% | 3.84% | -4.19% | -16.36% | -24.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.71% | 2.64% | 17.71% | 1.65% | 1.67% |
| Operating Income | 183.10% | 327.64% | -240.41% | 171.48% | 155.64% |
| Income Before Tax | 190.11% | 273.71% | -235.00% | 167.63% | 153.39% |
| Income Tax Expenses | 149.26% | 215.40% | -18.49% | 5,955.56% | 497.59% |
| Earnings from Continuing Operations | 201.91% | 292.32% | -325.24% | 156.15% | 142.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 201.91% | 292.32% | -325.24% | 156.15% | 142.70% |
| EBIT | 183.10% | 327.64% | -240.41% | 171.48% | 155.64% |
| EBITDA | 159.07% | 257.86% | -177.28% | 202.03% | 170.94% |
| EPS Basic | 159.41% | 224.32% | -294.48% | 158.32% | 145.29% |
| Normalized Basic EPS | 152.68% | 214.58% | -218.47% | 169.94% | 155.88% |
| EPS Diluted | 399.34% | 1,251.85% | -14,683.33% | 130.98% | 120.78% |
| Normalized Diluted EPS | 265.28% | 510.17% | -437.04% | 141.82% | 137.58% |
| Average Basic Shares Outstanding | 6.55% | 8.04% | 8.26% | 4.19% | 2.68% |
| Average Diluted Shares Outstanding | -5.09% | -3.22% | -4.12% | 14.27% | 13.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |